title: Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients.
abstract: The aims of this study were to determine the clinical and histological characteristics of melanoma in transplant recipients, the mutation profile (BRAF, NRAS and c-KIT genes), and the immune tolerance of the tumour microenvironment by immunohistochemical study of the expression of indoleamine 2,3-dioxygenase (IDO), PD1, PD-L1, CD8 and FoxP3. The study population comprised patients who had undergone a renal transplant in Nantes University Hospital who developed post-transplantation melanoma. Twenty cases of melanoma out of 4,663 transplant recipients were studied. The results differed from the usual data with respect to melanoma site: 40% were located on the face and were of the malignant lentigo type. The mutation profile was concordant with that of the immunocompetent population. IDO was expressed in all the sections tested, while CD8, FoxP3, PD1 and PD-L1 were poorly expressed. This reflected a highly immunodepressed tumour environment, raising the question of the inductive role of IDO on tumour immune tolerance in patients presenting with long-term immunodepression.
authors.affiliation: Department of Dermatology, Nantes University Hospital, INSERM, 892, FR-44000 Nantes, France.
authors.forename: Anabelle
authors.initials: A
authors.lastname: Brocard
authors.forename: Anne-Chantal
authors.initials: AC
authors.lastname: Knol
authors.forename: Céline
authors.initials: C
authors.lastname: Bossard
authors.forename: Marc Guillaume
authors.initials: MG
authors.lastname: Denis
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Quéreux
authors.forename: Mélanie
authors.initials: M
authors.lastname: Saint-Jean
authors.forename: Lucie
authors.initials: L
authors.lastname: Peuvrel
authors.forename: Amir
authors.initials: A
authors.lastname: Khammari
authors.forename: Gilles
authors.initials: G
authors.lastname: Blancho
authors.forename: Jacques
authors.initials: J
authors.lastname: Dantal
authors.forename: Brigitte
authors.initials: B
authors.lastname: Dréno
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D060890:B7-H1 Antigen / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D004252:DNA Mutational Analysis; D005260:Female; D051858:Forkhead Transcription Factors / Q000032:analysis; D020558:GTP Phosphohydrolases / Q000235:genetics; D020022:Genetic Predisposition to Disease; D006801:Humans; D007108:Immune Tolerance; D007113:Immunity, Innate / Q000187:drug effects; D016867:Immunocompromised Host; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000009:adverse effects; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000032:analysis; D016030:Kidney Transplantation / Q000009:adverse effects*; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D008297:Male; D008545:Melanoma / Q000235:genetics* / Q000276:immunology*; D008565:Membrane Proteins / Q000235:genetics; D008875:Middle Aged; D009154:Mutation; D010641:Phenotype; D061026:Programmed Cell Death 1 Receptor / Q000032:analysis; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D012189:Retrospective Studies; D012307:Risk Factors; D012878:Skin Neoplasms / Q000235:genetics* / Q000276:immunology*; D013997:Time Factors; D016896:Treatment Outcome; D019139:Tumor Escape; D059016:Tumor Microenvironment; D055815:Young Adult
chemical_list: D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; C423236:CD274 protein, human; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D007166:Immunosuppressive Agents; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D008565:Membrane Proteins; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D019009:Proto-Oncogene Proteins c-kit; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020558:GTP Phosphohydrolases; C579846:NRAS protein, human